PMID- 21809115
OWN - NLM
STAT- MEDLINE
DCOM- 20120913
LR  - 20171116
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 129
IP  - 3
DP  - 2011 Oct
TI  - The role of topoisomerase IIalpha in predicting sensitivity to anthracyclines in 
      breast cancer patients: a meta-analysis of published literatures.
PG  - 839-48
LID - 10.1007/s10549-011-1694-9 [doi]
AB  - Topoisomerase IIalpha is not only a proliferation marker of tumor cells, but is also 
      a target for anthracycline-based chemotherapy. Both in vitro and in vivo studies 
      have shown that there is a relationship between topo IIalpha and chemosensitivity to 
      anthracyclines, but the predictive role of topo IIalpha in breast cancer patients is 
      still controversial. A meta-analysis based on published studies was performed to 
      obtain an accurate assessment of the association between topo IIalpha and sensitivity 
      to anthracycline-based chemotherapy. A total of 13 eligible studies, including 
      2,633 cases and 2,118 controls were identified. Topo IIalpha was associated with 
      sensitivity to anthracyclines in locally advanced breast cancer patients who 
      received neoadjuvant chemotherapy [five studies, including three using 
      fluorescence in situ hybridization (FISH) and two using immunohistochemistry 
      (IHC): relative risk (RR) = 1.93, 95% confidence interval (95% CI): 1.27-2.94, P 
      = 0.002; two using FISH and three using IHC: RR = 1.98, 95% CI: 1.37-2.86, P < 
      0.001]. This association existed among three studies using FISH (RR = 2.03, 95% 
      CI: 1.14-3.61, P = 0.017), but did not exist among three studies using IHC (P > 
      0.05). In early-stage breast cancer patients who received anthracycline-based 
      adjuvant chemotherapy compared with non-taxane-based polychemotherapy, 
      amplification [hazard ratio (HR) = 0.64, 95% CI: 0.49-0.83, P = 0.001; HR = 0.59, 
      95% CI: 0.35-1.01, P = 0.056] or deletion (HR = 0.82, 95% CI: 0.67-1.00, P = 
      0.051; HR = 0.58, 95% CI: 0.35-0.97, P = 0.036) of topo IIalpha was significantly 
      associated with better recurrence-free survival and overall survival. In summary, 
      the present meta-analysis suggests that topo IIalpha is a predictive factor for 
      breast cancer patients who receive anthracycline-based chemotherapy. Larger and 
      well-designed prospective studies are required to further evaluate the predictive 
      role of topo IIalpha in clinical practice.
FAU - Du, Yueyao
AU  - Du Y
AD  - Department of Breast Surgery, Shanghai Cancer Center, Fudan University, 399 
      Ling-Ling Road, Shanghai 200032, China.
FAU - Zhou, Qiong
AU  - Zhou Q
FAU - Yin, Wenjin
AU  - Yin W
FAU - Zhou, Liheng
AU  - Zhou L
FAU - Di, Genhong
AU  - Di G
FAU - Shen, Zhenzhou
AU  - Shen Z
FAU - Shao, Zhimin
AU  - Shao Z
FAU - Lu, Jinsong
AU  - Lu J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20110802
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Anthracyclines)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - EC 5.99.1.3 (DNA Topoisomerases, Type II)
SB  - IM
MH  - Anthracyclines/*therapeutic use
MH  - Antibiotics, Antineoplastic/*therapeutic use
MH  - Antigens, Neoplasm/genetics/*metabolism
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Breast Neoplasms/*drug therapy/*enzymology/mortality/pathology
MH  - Chemotherapy, Adjuvant
MH  - DNA Topoisomerases, Type II/genetics/*metabolism
MH  - DNA-Binding Proteins/genetics/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Neoplasm Staging
MH  - Predictive Value of Tests
EDAT- 2011/08/03 06:00
MHDA- 2012/09/14 06:00
CRDT- 2011/08/03 06:00
PHST- 2011/05/04 00:00 [received]
PHST- 2011/07/21 00:00 [accepted]
PHST- 2011/08/03 06:00 [entrez]
PHST- 2011/08/03 06:00 [pubmed]
PHST- 2012/09/14 06:00 [medline]
AID - 10.1007/s10549-011-1694-9 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2011 Oct;129(3):839-48. doi: 10.1007/s10549-011-1694-9. 
      Epub 2011 Aug 2.